Reaction

Stenosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,832 reports · 45 co-occurring drugs

As of the last recalculation, Stenosis appears in 1,832 FAERS reports alongside 45 co-occurring drug terms. The strongest observed disproportionality signal is EPLERENONE (PRR 26.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Eplerenone	29	26.1	26.2
Cefuroxime	18	18.1	18.1
Doxepin	15	16.9	17.0
Risankizumab-Rzaa	111	16.4	16.4
Telmisartan	24	15.5	15.5
Adalimumab-Fkjp	61	15.4	15.5
Adalimumab-Aaty	62	15.4	15.4
Linagliptin	24	15.1	15.2
Doxepin Hydrochloride	16	14.5	14.5
Adalimumab-Adaz	65	14.5	14.5
Vedolizumab	93	12.9	12.9
Azathioprine	94	12.7	12.7
Infliximab-Dyyb	32	12.6	12.7
Upadacitinib	84	12.2	12.2
Oxazepam	22	11.8	11.8
Inclisiran	8	11.4	11.4
Meperidine Hydrochloride	9	11.1	11.2
Fenofibrate	34	11.1	11.1
Quinine	8	10.6	10.6
Indapamide	16	10.2	10.2
Ticagrelor	28	10.1	10.1
Ustekinumab	87	10.1	10.1
Clobazam	21	9.9	9.9
Rabeprazole	19	9.8	9.8
Metronidazole Topical	39	9.5	9.5
Nilotinib	24	9.4	9.4
Tramadol Hydrochloride	30	9.2	9.2
Adalimumab	426	8.6	8.6
Labetalol	10	8.6	8.6
Insulin Glargine-Yfgn	16	8.4	8.4
Mercaptopurine	12	7.9	7.9
Clopidogrel Bisulfate	67	7.7	7.7
Nicotine Polacrilex Mini	10	7.6	7.6
Nicotine Polarilex	10	7.6	7.6
Bleomycin Sulfate	6	6.6	6.6
Ribociclib	17	6.2	6.2
Prasugrel Hydrochloride	5	5.6	5.6
Rucaparib	4	5.2	5.2
Tafamidis	5	4.8	4.8
Ravulizumab	5	4.2	4.2
Palivizumab	4	3.0	3.0
Emicizumab	3	2.8	2.8
Tapentadol Hydrochloride	8	2.7	2.7
Abaloparatide	5	1.9	1.9
Evolocumab	20	1.4	1.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.